The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Malyutin A.V.

Angelini Pharma Rus, Moscow, Russia

Pikalov A.A.

Sunovion Pharmaceuticals Inc, USA

Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine

Authors:

Mosolov S.N., Malyutin A.V., Pikalov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12): 29‑37

DOI: 10.17116/jnevro201911912129

Read: 4120 times

Download PDF (RU)
Contact the author
Table of contents

EFFECT OF LURASIDONE ON SYMPTOMS OF SCHIZOPHRENIA IN FIVE-FACTOR DIMENSIONAL MODEL: POOLED ANALYSIS OF TWO SHORT-TERM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES IN PATIENTS FROM RUSSIA AND UKRAINE
EFFECT OF LURASIDONE ON SYMPTOMS OF SCHIZOPHRENIA IN FIVE-FACTOR DIMENSIONAL MODEL: POOLED ANALYSIS OF TWO SHORT-TERM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES IN PATIENTS FROM RUSSIA AND UKRAINE

To cite this article:

Mosolov SN, Malyutin AV, Pikalov AA. Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12):29‑37. (In Russ.)
https://doi.org/10.17116/jnevro201911912129

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The rela­tionship between inflammatory markers, fati­gue, and effort-based deci­sion-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
Neuronal models based on olfa­ctory epithelial cells in the study of the pathogenesis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Abstract:

Objective. Evaluation of a new five-factor dimensional model of schizophrenia in recent revisions of classifications of mental disorders (DSM-5 and ICD-11) dictates the need to use this approach in conducting a comprehensive assessment of the effectiveness of new antipsychotic agents, including ethnically homogeneous populations of patients. Material and methods. Post-hoc analysis of pooled data from two randomized, double-blind, placebo-controlled, 6-week clinical studies (RCTs) of lurasidone (fixed doses, 40, 80, 120 or 160 mg/d) in patients experiencing an acute exacerbation of schizophrenia. Changes in PANSS total score, CGI-S score and five established PANSS factors were assessed using mixed-model repeated measures analysis. Results. Lurasidone (n=162, dose groups pooled) compared with placebo (n=68), significantly improved the PANSS total score at Week 6 (–23.0 vs. –10.5; p<0.001; effect size 0.82) as well as all PANSS factor scores: positive symptoms (–8.5 vs. –4.2; p<0.001; effect size 0.88), negative symptoms (–4.4 vs. –2.8; p=0.011, effect size 0.44), disorganized thoughts (–4.4 vs. –2.1; p<0.001; effect size 0.70), hostility/excitement (–2.7 vs. –0.7; p<0.001; effect size 0.66), and depression/anxiety (–3.5 vs. –2.2; p=0.002; effect size 0.53). Conclusion. Lurasidone demonstrated significant improvement for both PANSS total score and each of the five PANSS factor scores, indicating effectiveness across the broad spectrum of schizophrenia symptoms. Effect size for both PANSS total score and each of the five PANSS factor scores for the local population was higher than for the wider population, which included patients from various countries.

Keywords:

lurasidone
atypical antipsychotic
schizophrenia
factor analysis

Authors:

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Malyutin A.V.

Angelini Pharma Rus, Moscow, Russia

Pikalov A.A.

Sunovion Pharmaceuticals Inc, USA

Close metadata

References:

  1. Andreasen NC, Olsen S. Negative vs. positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789-794. https://doi.org/10.1001/archpsyc.1982.04290070025006
  2. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980;280:66-68. https://doi.org/10.1136/bmj.280.6207.66
  3. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995;52:352-360. https://doi.org/10.1001/archpsyc.1995.03950170026004
  4. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q. 1994;65:299-322. https://doi.org/10.1007/bf02354306
  5. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28:22-31. https://doi.org/10.1159/000284896
  6. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538-546. https://doi.org/10.4088/jcp.v58n1205
  7. Nakaya M, Suwa H, Ohmori K. Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr Res. 1999;39:39-50. https://doi.org/10.1016/s0920-9964(99)00018-3
  8. Peralta V, Cuesta MJ. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res. 2001;49:269-285. https://doi.org/10.1016/s0920-9964(00)00071-2
  9. Lancon C, Auquier P, Nayt G, Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2000;42:231-239.
  10. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551-556. https://doi.org/10.4088/jcp.v65n0416
  11. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012;137:246-250. https://doi.org/10.1016/j.schres.2012.01.031
  12. Kay SR, Sevy S. Pyramidal model schizophrenia. Schizophr Bull. 1990;16:537-545.
  13. Lindenmayer JP, Grochovski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14:229-234. https://doi.org/10.1016/0920-9964(94)00041-6
  14. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001;62:797-803. https://doi.org/10.4088/jcp.v62n1008
  15. Mosolov SN. Shkaly psihometricheskoj ocenki simptomatiki shizofrenii i koncepcija pozitivnyh i negativnyh rasstrojstv. M.: Novyj cvet; 2001. (In Russ.)
  16. Mosolov S, Potapov AV, Ushakov UV, Shafarenko AA, Kostyukova AB. Design and validation of standardized clinical and functional remission criteria in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:167-181. https://doi.org/10.2147/ndt.s46799
  17. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011;131:75-81. https://doi.org/10.1016/j.schres.2011.05.018
  18. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62:757-771. https://doi.org/10.4088/jcp.v62n1003
  19. Kim JH, Kim SY, Lee J, Oh KJ, Kim YB, Cho ZH. Evaluation of the factor structure of symptoms in patients with schizophrenia. Psychiatry Res. 2012;197:285-289. https://doi.org/10.1016/j.psychres.2011.10.006
  20. Van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, Hert M, Cuijpers A, Wiersma D. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res. 2006;85:280-287. https://doi.org/10.1016/j.schres.2006.03.021
  21. Lepine JP, Piron JJ, Chapatot E. Factor analyses of the PANSS in schizophrenia. Psychiatry Today: Accomplishments and promises. Amsterdam: Exerpta Media; 1989.
  22. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer J-P. Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psych Res. 1994;52:295-303. https://doi.org/10.1016/0165-1781(94)90075-2
  23. Kawasaki Y, Maeda Y, Sakai N, Higashima M, Urata K, Yamaguchi N, Kurachi M. Evaluation and interpretation of symptom structures in patients with schizophrenia. Acta Psychiat Scand. 1994;89:399-404. https://doi.org/10.1111/j.1600-0447.1994.tb01536.x
  24. Mosolov SN. Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;110:6:4-11. (In Russ.)
  25. Mosolov SN, Kuzavkova MV, Kalinin VV, Eremin AV, Sulimov GY. Analysis of the influence of atypical Antipsychotics on a 5-Factor Model of Schizophrenia. Social’naja i Klinicheskaja Psihiatrija. 2003;13:3:45-52. (In Russ.)
  26. Mosolov SN, Tsukarzi EE, Kapiletti SG. Antipsihoticheskaja farmakoterapija shizofrenii: ot nauchnyh dannyh k klinicheskim rekomendacijam. V kn.: Biologicheskie metody terapii psihicheskih rasstrojstv. Red. Mosolov S.N. Dokazatel’naja medicina — klinicheskoj praktike. M. 2012. (In Russ.)
  27. Mosolov SN, Tsukarzi EE. Psihofarmakoterapija shizofrenii. V kn.: Psihiatrija: nacional’noe rukovodstvo. Pod red. Neznanov N.G., Aleksandrovskij Ju.A. M. 2018. (In Russ.)
  28. Juckel G, de Bartolomeis A, Gorwood Ph, Mosolov S, Pani L, Rossi A, Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:1867-1878. https://doi.org/10.2147/ndt.s61672
  29. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=602aa9b9-50a7-42fc-adef-4af0fb8b71d9&t=
  30. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101-109. https://doi.org/10.1016/j.schres.2013.01.009
  31. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957-967. https://doi.org/10.1176/appi.ajp.2011.10060907
  32. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829-836. https://doi.org/10.4088/JCP.08m04905
  33. Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, Loebel A. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670-677. https://doi.org/10.1016/j.jpsychires.2013.01.020
  34. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225:519-530. https://doi.org/10.1007/s00213-012-2838-2
  35. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160-168. https://doi.org/10.1176/appi.ajp.2013.13070984
  36. Loebel A, Cucchiaro J, Silva R, Kroger H, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169-177. https://doi.org/10.1176/appi.ajp.2013.13070985
  37. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview- based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188-194. https://doi.org/10.1016/j.schres.2011.01.004
  38. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23:1373-1382. https://doi.org/10.1016/j.euroneuro.2013.08.003
  39. Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2014;23:1-8. https://doi.org/10.1017/s1092852914000285
  40. Loebel A, Cucchiaro J, Silva R, Mao Y, Xu J, Pikalov A, Marder SR. Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies. European Psychiatry. 2015;30:26-31. https://doi.org/10.1016/j.eurpsy.2014.08.001
  41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders.4th ed. Washington, DC: American Psychiatric Press; 1994 (DSM IV).
  42. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
  43. Latuda Assessment report (EMA/113836/2014) Rev05.13 Page 118/147.
  44. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009;70:25-35. https://doi.org/10.4088/jcp.08m04310
  45. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30:106-115. https://doi.org/10.1097/jcp.0b013e3181d35d6b
  46. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147-150. https://doi.org/10.1016/j.schres.2012.01.015
  47. Mosolov SN, Tsukarzi EE, Alfimov PV. Algorithms for biological treatment of schizoprenia. Sovremennaja Terapija Psihicheskih Rasstrojstv. 2014;1:27-36. (In Russ.)
  48. Maslenikov NV, Tsukarzi EE, Mosolov SN. Algorithm of Biological Treatment for Depression in Schizophrenia. Sovremennaja Terapija Psihicheskih Rasstrojstv. 2019;2:31-40. (In Russ.)
  49. Potkin SG, Phiri P, Szegedi A, Zhao J, Alphs L, Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res. 2013;150:442-449. https://doi.org/10.1016/j.schres.2013.08.024
  50. Bell MD, Lysaker PH. Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatr Serv. 1995;46:508-510. https://doi.org/10.1176/ps.46.5.508
  51. Erickson M, Jaafari N, Lysaker P. Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Res. 2011;189:161-165.
  52. Llorca PM, Blanc O, Samalin L, Bosia M, Cavallaro R. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiatry. 2012;27:396-400. https://doi.org/10.1016/j.eurpsy.2011.01.010
  53. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97-100. https://doi.org/10.1016/j.psychres.2008.10.009
  54. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:189-199. https://doi.org/10.1016/j.schres.2009.03.035
  55. Pandina G, Bilder R, Turkoz I, Alphs L. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res. 2013;143:312-318. https://doi.org/10.1016/j.schres.2012.11.031
  56. Amore M, Menchetti M, Tonti C, Scarlatti F, Lundgren E, Esposito W, Berardi D. Predictors of violent behavior among acute psychiatric patients: clinical study. Psychiatry Clin Neurosci. 2008;62:247-255. https://doi.org/10.1111/j.1440-1819.2008.01790.x
  57. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163:418-425. https://doi.org/10.1176/appi.ajp.163.3.418
  58. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35:383-402. https://doi.org/10.1093/schbul/sbn135
  59. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90:186-197. https://doi.org/10.1016/j.schres.2006.09.027
  60. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001;62:797-803. https://doi.org/10.4088/jcp.v62n1008
  61. Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome LL, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res. 2005;39:109-115. https://doi.org/10.1016/j.jpsychires.2004.04.010
  62. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003;108:297-303. https://doi.org/10.1034/j.1600-0447.2003.00132.x
  63. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25:157-171. https://doi.org/10.1093/oxfordjournals.schbul.a033362
  64. Schwartz RC, Cohen BN. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry. 2001;42:118-123. https://doi.org/10.1053/comp.2001.21222
  65. Siris SG. Depression in schizophrenia: perspective in the era of «atypical» antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389. https://doi.org/10.1176/appi.ajp.157.9.1379
  66. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15:127-135. https://doi.org/10.1177/026988110101500209
  67. Soyka M, Graz C, Bottlender R, Dirschedl P, Schoech H. Clinical correlates of later violence and criminal offences in schizophrenia. Schizophr Res. 2007;94:89-98. https://doi.org/10.1016/j.schres.2007.03.027
  68. Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Scott Stroup T, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006;63:490-499. https://doi.org/10.1001/archpsyc.63.5.490
  69. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A. Effectiveness of Lurasidone in Schizophrenia or Schizoaffective Disorder Patients Switched from Other Antipsychotics: A Randomized, Six-Week, Open-Label, Study. J Clin Psychiatry. 2013;74(2):170-179. https://doi.org/10.4088/jcp.12m07992
  70. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29:127-136. https://doi.org/10.1016/j.euroneuro.2018.10.008
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.